(Boursier.com) — Mauna Kea Technologies climbed 16% to 0.69 euro this Friday, while the inventor of Cellvizio, the multidisciplinary platform for confocal laser endomicroscopy by miniprobe and by needle (p/nCLE), announced its sales for the 1st quarter of 2023, ended on March, 31st. Total revenue amounted to 4,168 KE in the first quarter of 2023, up 121% compared to the same period in 2022, benefiting from the recognition of the first license and technology royalty income related to the Joint Venture with Tasly Pharmaceutical. Revenues from the Joint Venture amounted to 2.8 ME during the past quarter, they are composed of a non-recurring part of 2.3 ME and a recurring part of 0.5 ME per quarter until at the end of the 2025 financial year, this income being already fully secured.
Portzamparc points out that the drop in sales is “misleading” and that the 5 new installations in the USA confirm the good dynamics of the group across the Atlantic. Enough to revise its target price upwards from 0.90 to 0.92 euro taking into account the additional upfront from Tasly. The analyst’s opinion remains buy.
©2023 Boursier.com